Modifiable risk factors impact CVD mortality in T2DM

Modifiable risk factors impact CVD mortality in T2DM

(HealthDay)—Modifiable risk factors can be targeted for early and continued intervention to reduce the risk of adverse outcomes in patients with type 2 diabetes mellitus and cardiovascular disease, according to research published online July 2 in Diabetes Care.

Amanda J. Cox, Ph.D., of the Wake Forest School of Medicine in Winston-Salem, N.C., and colleagues analyzed data for a subset of 371 high-risk patients from the Diabetes Heart Study with type 2 diabetes and a coronary artery calcified plaque score greater than 1,000 mg. The researchers compared differences in (CVD) risk factors among 218 living and 153 deceased participants.

The researchers found that duration of type 2 diabetes had been longer (P = 0.02) and use of cholesterol-lowering medications lower (P = 0.004) among deceased participants. After adjustment, vascular calcified plaque scores were found to be associated with higher risk of mortality. Other CVD risk factors found to be associated with 1.1 to 1.5 times higher risk of mortality included higher levels of HbA1c, lipids, and C-reactive protein and reduced kidney function.

"In conclusion, the findings described here suggest that even among individuals with type 2 diabetes and high burden of subclinical CVD, modifiable exist that could be targeted for early and continued intervention to reduce the risk of ," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Serum marker predicts cardiovascular events in diabetes

Apr 25, 2014

(HealthDay)—Elevated levels of polyclonal serum immunoglobulin combined free light chains (cFLCs) may indicate adverse cardiovascular disease (CVD) outcomes in patients with type 2 diabetes, according to ...

Heart health matters to your brain

Jun 04, 2013

June 4, 2013 – People suffering from type 2 diabetes and cardiovascular disease (CVD) are at an increased risk of cognitive decline, according to a new study from Wake Forest Baptist Medical Center.

Recommended for you

Study explores effects of metformin in obese children

Dec 18, 2014

(HealthDay)—For obese hyperinsulinemic children, metformin seems to decrease perceived hunger and increase perceived fullness, according to a study published online Dec. 8 in Diabetes, Obesity and Metabolism.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.